What Regal Treats: Main Uses and Benefits

Regal is a multi-component preparation applied across domains where additional symptomatic support is needed, contributing to easing the overall symptom load during difficult episodes. The therapeutic role of this category of agents is relevant when supportive symptom management is appropriate for anorectal conditions.

The medicine is commonly used across conditions presenting with acute episodes. It is relevant for easing symptoms related to inflammatory or irritative states, such as localized burning, soreness, itching, and minor local swelling. It is also applied in scenarios where additional management of discomfort is required due to straining associated with occasional constipation.

This provides symptomatic relief that supports patients during difficult episodes by easing distress. The preparation may help patients cope more steadily with symptom fluctuations, supporting general well-being during symptomatic phases.

Quick Fact: Relief for Straining
The preparation is relevant in conditions where symptoms may intensify temporarily due to discomfort associated with straining or difficult bowel movements.

Regulatory References

1. Health Canada Labelling Standard for Anorectal Drug Products

Eligibility Map: Who Can and Cannot Use Regal

The official eligibility profile for Regal is determined by regulatory standards, focusing on patient age, physical condition, and known sensitivities.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults and adolescents 12 years of age and older are the established population for standard use.
Populations for whom use is not recommended	Children younger than 2 years old are not recommended to use this preparation without consulting a physician.
	Pregnant and breastfeeding individuals must seek advice from a healthcare professional prior to use.
Populations for whom use is contraindicated	Individuals with a known hypersensitivity or allergy to Resorcinol, Docusate, Zinc Chloride, or any other component of the preparation.

Eligibility-Related Restrictions

• Topical Limitation: The medicine is restricted from use on open wounds, raw surfaces, or blistered areas, and must not be applied over large areas of the body.
• Conditional Pediatric Use: Use in children aged 2 to 11 years requires mandatory consultation with a physician.

Connection to the Overall Eligibility Profile

Regulatory documents define eligibility primarily by establishing an Absolute Contraindication for ingredient allergies and a strong age-based exclusion for infants. Use is conditionally restricted where the risk of systemic absorption is heightened, such as over broken skin or during pregnancy and lactation.

Interactions with other medicines and products

The official regulatory profile for Regal, a multi-component topical anorectal preparation, addresses interactions primarily through constraints on co-administration with other substances and topical agents. These documented interaction patterns relate to exposure modification, additive local effects, and population-specific restrictions.

Interaction Classifications (High-Level)

Interaction Classification	Interacting Entity	Official Regulatory Restriction
Contraindicated Combination	Topical Mercury-Containing Preparations	Strict avoidance of co-application on the same area due to chemical incompatibility with the Resorcinol component.
Exposure-Modifying Interaction	Mineral Oil Laxatives	Caution required due to the Docusate component potentially enhancing the systemic absorption of the mineral oil.
Pharmacodynamic Interaction	Other Topical Irritants or Peeling Agents	Restriction on co-application due to the risk of severe additive skin irritation with the Resorcinol component.
Electrolyte-Altering Interaction	Diuretics or Potassium Supplements	Chronic or excessive use of the Docusate component may result in reduced serum potassium concentrations, altering the effect of these medicines.

Regulatory documentation also includes a Population-Specific Restriction for Infants and Children, advising against use over large surface areas or wounds due to the increased potential for systemic absorption of the Resorcinol component in this population. This structure formalizes specific, label-based restrictions concerning co-use with select medicinal products and substances.

How Regal Works: Mechanism of Action

Regal is a multi-component preparation whose mechanism involves the complementary interaction of three distinct local processes.

Modulation of Fecal Biomechanics

This domain involves the action of the anionic surfactant, Docusate, which targets the lipid-water interface within the fecal mass. By significantly reducing surface tension, Docusate facilitates the integration of water and lipids into the stool structure. This physical alteration results in a more pliable, softer fecal mass, which reduces the magnitude of mechanical stress exerted on the tissue during passage.

️ Local Structural Modulation via Astringency

The astringent components, including Zinc Chloride and botanical tannins, chemically interact with superficial tissue proteins on mucosal and capillary surfaces. This localized protein coagulation temporarily constricts the tissue and reduces capillary permeability. The physiological consequence of this structural change is the reduction in local fluid extravasation and tissue volume.

Topical Protective Barrier and Antiseptic Action

A protective protein-tannin film is formed over the tissue surface, serving as a physical barrier against external contact and contaminants. This action is complemented by the non-specific antiseptic mechanism of Resorcinol and Zinc Chloride, which disrupt microbial enzymes on the surface, reducing local surface microbial proliferation.

Instruction Map: How to use Regal — official administration guidelines

This section summarizes the official usage guidelines for Regal's Milk of Magnesia Oral Solution, based on documented administration rules.

Administration scope	Detail
Route of administration:	Oral Solution (by mouth).
Dosing schedule:	Take in the dose and duration as advised by a physician. It is typically taken once a day as needed for up to 2 weeks.
Timing in relation to meals (if applicable):	May be taken with or without food, but it is better to take it at a fixed time. Take at least 2 hours after taking other medicines, as it may interfere with the absorption of other medicines.
Preparation requirements (if applicable):	Shake well before use. Measure the dose using a measuring cup or device.
Age-group administration rules:	Safety and dosing for specific age groups must be determined by the prescriber.
Missed-dose rules:	Do not take an extra dose to make up for a missed one.
Special procedural conditions:	Preferably taken at bedtime, as it requires 6 to 8 hours to show effect. Not for long-term use.

---

Instruction classifications (high-level)

Classification	Detail
Administration method type:	Oral (Liquid)
Frequency pattern:	As-needed (typically once daily)
Regulatory basis:	Monograph/General medical practice (consistent with non-prescription standards).
Use-context constraints:	Used for minor or occasional cases; not for long-term use. Must be taken 2 hours apart from other medications.

---

Resulting procedural structure

Official step sequence:

• Shake the oral solution well before administering.
• Measure the prescribed dosage accurately using a measuring device.
• Take the medicine by mouth, typically once daily at a fixed time, preferably at bedtime.
• Ensure that this medication is taken at least 2 hours apart from other prescribed medicines.

Connection to the overall use protocol (2–4 sentences): The official protocol for using Regal’s Milk of Magnesia is a straightforward, single-route administration schedule focused on evening use to align with the product’s 6 to 8-hour onset of effect. The instructions emphasize accurate measurement and separation from other medications to ensure proper absorption and effectiveness, adhering to standard content requirements for dosage and administration sections in drug labeling.

Research Evidence / Overview of Studies for Regal

This overview summarizes the official research evidence that exists for the active ingredients found in Regal, focusing on the design of the studies, the outcomes that research has explored, and the areas where the scientific understanding is still developing. This information is drawn from authoritative governmental sources and peer-reviewed scientific literature to provide context for the medicine's role in managing anorectal symptoms.

---

Evidence for Symptom Relief from Topical Components

The regulatory evaluation for this class of multi-component topical preparations is informed by the status of its active ingredient categories, such as astringents and emollients, as described in official governmental standards or monographs. This includes information that these ingredient classes are classified as Generally Recognized as Safe and Effective (GRASE) for topical anorectal use in those regulatory contexts.

Research has explored this class of topical agents in short-term comparative studies and smaller Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time and were relevant in trials assessing short-term or episodic symptom patterns. Researchers primarily monitored patient-reported outcomes describing perceived discomfort, such as the frequency and severity of itching, burning, and localized soreness.

Evidence Related to Bowel Function and Straining Discomfort

Research explored the Docusate component's association with measurements related to systemic or functional imbalance. This component was monitored in studies examining the relationship between it and occasional constipation, as well as the resulting physiological strain or stress that may affect anorectal discomfort. The outcomes research examined in these trials included changes in objective measures like stool consistency and spontaneous bowel movement frequency.

However, the evidence base for the surfactant component is marked by significant variability across studies. Multiple systematic reviews have noted a low quality assessment score for many of the historical trials, which introduces uncertainty. Furthermore, some high-quality, contemporary studies monitored the impact of this ingredient on core functional measures like stool frequency and findings were mixed, with some trials observing no statistically significant difference from a placebo.

What Remains Uncertain and Areas for Future Study

Data for certain groups remain insufficient. For instance, there is limited information about the outcomes related to physical discomfort in specific subgroups, such as older adults with multiple chronic conditions. The primary objective of the research for this category has typically been the evaluation of symptom changes during acute episodes. Consequently, long-term effects are not fully established, and comparative evidence is lacking to definitively establish the incremental benefit of the full combination versus single-ingredient products or placebo across all measured outcomes.

Key Studies & References

1. Health Canada Labelling Standard for Anorectal Drug Products

Common questions about Regal (FAQ)

Q: What is the main approved use of Regal?

According to the official product information for its active ingredients, Regal is generally indicated to help relieve the pain, itching, and burning associated with symptoms such as hemorrhoids and other anorectal disorders. The medicine's purpose is described as providing symptomatic relief, tissue support, and reduced straining for these conditions.

Q: What is the typical time frame to see or feel any changes after starting Regal?

The official instructions indicate that the product is preferably taken at bedtime, as its onset of effect typically requires 6 to 8 hours. However, the regulatory documentation does not specify the typical time frame required for a complete change in symptoms or the full duration of an entire course of treatment.

Q: Are there any common side effects people report when starting Regal?

Regulatory documents list several possible adverse effects, which may include localized irritation, burning, stomach cramps, nausea, and diarrhea. Official sources do not specify the frequency (e.g., common or rare) for these reactions.

Q: Is Regal safe for use in older adults?

Use is generally permitted for adults 12 years and older. However, official regulatory documents note that research data remains limited for specific subgroups, such as older adults with multiple chronic conditions. Use in this population may require consideration of the limited research data mentioned in the regulatory context.

Q: Why are there different strengths or formulations of Regal?

Regal is classified as a multi-component preparation, meaning it combines several active ingredients. It may be supplied in various forms, such as an ointment, suppository, or solution, to function as a multi-action topical agent. The official documentation does not detail the specific reasons for choosing one form over another.

Q: What does the FDA / EMA say about the evidence for Regal?

The regulatory assessment for the ingredients in Regal is informed by their classification as Generally Recognized as Safe and Effective (GRASE) for topical anorectal use in certain regulatory contexts. Official sources do not provide a concise summary of the overall evidence themes from specific studies.

Q: How is Regal processed by the body?

Regal is intended for local topical action on the affected area. However, warnings regarding the Resorcinol component indicate a risk of systemic toxicity (poisoning) if the product is applied excessively or over large or broken skin areas, which suggests that some absorption into the body can occur.

Q: What is the difference between the brand name Regal and its generic name?

Regal is a brand name for a combination product and does not have a single generic name. Instead, its therapeutic effects rely on the combined action of multiple active ingredients, including synthetic compounds like Docusate, Resorcinol, and Zinc Chloride, along with various botanical tinctures.

Q: How is the safety profile of Regal generally described in official sources?

Official sources describe a safety profile that includes expected local adverse reactions, such as irritation and burning. These serious risks include the potential for systemic toxicity associated with excessive use or application over large or broken skin areas, as well as the risk of a severe allergic reaction (anaphylaxis) related to the Docusate component.

Q: What is the maximum duration of treatment with Regal that has been studied?

Official usage instructions indicate that the medicine is typically taken for up to 2 weeks, and the side effects section suggests not using it for more than one week. The research evidence that informed the regulatory profile involved short-term comparative studies, but a definitive, stated maximum duration from a specific clinical trial is not explicitly documented.

Q: Why is Regal restricted for use in certain age groups?

Regulatory documents restrict the use of Regal in children younger than 2 years old primarily because the pediatric population has an increased susceptibility to systemic effects from the skin absorption of the active components, particularly Resorcinol. Official documentation notes that the use of this product in children aged 2 to 11 years requires specific consultation with a physician.

Q: Can Regal be taken with other prescription medications?

Regal can be taken with other prescription medications, but there are specific restrictions. The official instructions indicate that Regal should be taken at least 2 hours apart from other medicines to prevent potential interference with their absorption. Additionally, the regulatory profile lists specific medicines that are contraindicated or require caution when co-administered.

Q: Is Regal a controlled substance?

Regulatory documentation for this type of over-the-counter topical agent generally indicates that it is not classified as a DEA Scheduled Controlled Substance.

Q: Does Regal cause fatigue or drowsiness?

Fatigue or drowsiness are not listed in the official documents as recognized side effects. Dizziness, a symptom of potential systemic toxicity, is noted in the documentation.

Q: Can Regal affect my mood or sleep?

Official documentation does not list mood changes or sleep issues as expected side effects. Symptoms of systemic toxicity, such as severe headache or dizziness, are noted in the documentation.

Q: Can people with liver or kidney issues use Regal?

Official regulatory information does not provide specific warnings or contraindications for individuals with liver disease. However, the regulatory documents suggest that consultation with a health professional is necessary prior to use in cases of kidney disease (renal impairment).

Q: What if I take Regal for a condition that is not listed on the label?

Official regulatory documents indicate that the medicine is only evaluated and cleared for the specific uses listed on the label, which relates to anorectal symptoms. The documentation implies that use for conditions not listed on the label is not supported by the product's official evaluation.

Q: Does Regal affect my ability to drive or operate machinery?

The regulatory documents do not provide a standard warning about driving impairment. However, since dizziness is a documented symptom of potential systemic toxicity, if a user experiences dizziness, caution may be necessary if driving or operating machinery.

Q: What should I do if I experience a serious adverse event while on Regal?

In the event of a severe allergic reaction (anaphylaxis) or symptoms of systemic toxicity, such as severe headache, slow heartbeat, or blue-colored skin (cyanosis), official regulatory sources indicate that immediate medical attention is necessary.

How to Store and Dispose of Regal

The storage and disposal of Regal (prasterone vaginal insert) must follow official regulatory requirements to ensure product integrity and safety.

---

Storage Requirements

The medicine must be kept at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with excursions permitted up to 30 C (86 F). The product must be protected from freezing and stored away from excessive heat and moisture. It is required to keep the medicine in its original container and ensure the container is tightly closed when not in use. Always store the product out of the reach of children.

---

Disposal Instructions

Unused or expired medication should be discarded properly. The preferred method is using a drug take-back program. If unavailable, the product may be disposed of in the household trash after mixing it with an undesirable substance, such as dirt or used coffee grounds, and placing the mixture in a sealed bag. Do not flush the product down a toilet or pour it down a drain.